Centella Asiatica (Expanded) for Blood Circulation

Research suggests that Centella asiatica, particularly its standardized triterpenic fraction (TTFCA), has meaningful evidence supporting its role in improving circulation and reducing symptoms associated with chronic venous insufficiency, including capillary leakage, ankle swelling, and poor microcirculation. A substantial body of randomized controlled trials from the early 1990s and 2000s consistently found that TTFCA reduced abnormal fluid leakage from small blood vessels and improved circulatory measures in patients with venous hypertension, and a more recent pilot study reported accelerated venous ulcer healing in patients taking a standardized Centella extract compared to standard care alone. Broader Cochrane meta-analyses examining the wider class of plant-derived vascular drugs known as phlebotonics — a category that includes Centella-derived compounds — found moderate-quality evidence for modest reductions in leg swelling, though these reviews noted limited evidence for ulcer healing, variable results across compounds, and a need for larger, longer-term trials. Overall, the evidence base is largely supportive in direction but limited by the age of many studies, relatively small sample sizes, and the fact that several reviews group Centella with other compounds rather than isolating its effects independently, so readers should weigh these findings accordingly.